Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02346955
Title Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001)
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

lung non-small cell carcinoma

melanoma

urinary bladder cancer

ovarian cancer

skin melanoma

colorectal cancer

stomach cancer

Therapies

CM-24

CM-24 + Pembrolizumab

Age Groups: adult
Covered Countries USA


No variant requirements are available.